Cytek Biosciences, Inc. - Common Stock, par value $0.001 per share (CTKB)

CUSIP: 23285D109

Q3 2024 13F Holders as of 30 Sep 2024

Holder snapshot 7 signals
Share change
-2,620,205
Put/Call ratio
0%
SEC-reported price per share
$5.54
Number of holders
134
Value change
-$14,542,700
Number of buys
84
Open additional details 1 more signal available
Number of sells
43
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
129,694,583

Security key

23285D109

Report period

Q3 2024

Institutions

134

Top holders

10

Ownership snapshot

Top reported holders of CTKB - Cytek Biosciences, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
0/15
Latest evidence
30 Jun 2024
3/4/5 13F Highest disclosed value: $127,120,013 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

RA CAPITAL MANAGEMENT, L.P. has the largest disclosed position value at $127.12M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Disclosed position value Top 5
RA CAPITAL MANAGEMENT, L.P. $127.12M
BlackRock Finance, Inc. $95.25M
VANGUARD GROUP INC $65.54M
BROWN CAPITAL MANAGEMENT LLC $63.54M
HHLR ADVISORS, LTD. $37.15M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
RA CAPITAL MANAGEMENT, L.P.
3/4/5
Director, 10%+ Owner
—
denominator unverified
$127,120,013
13,381,054 shares
— 14 Mar 2022
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$95,252,956
17,070,422 shares
— 30 Jun 2024
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$65,543,673
11,746,178 shares
— 30 Jun 2024
BROWN CAPITAL MANAGEMENT LLC
13F
Company
13F
—
denominator unverified
$63,541,603
11,387,384 shares
— 30 Jun 2024
HHLR ADVISORS, LTD.
13F
Company
13F
—
denominator unverified
$37,146,227
6,657,030 shares
— 30 Jun 2024
STATE STREET CORP
13F
Company
13F
—
denominator unverified
$22,170,077
3,973,132 shares
— 30 Jun 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
134
Shares
74,960,438
Rows available
134
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2024 vs Q4 2025 Across Filers

Q4 2025 holders
155
Q3 2024 holders
134
Holder diff
-21
Investor Q4 2025 Shares Q3 2024 Shares Share Diff Share Chg % Q4 2025 value Q3 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .